Which drugs compete with Stelara (ustekinumab)?
Stelara (ustekinumab) is a biologic used for several immune-mediated conditions, including plaque psoriasis and psoriatic arthritis, and it’s also used in Crohn’s disease and ulcerative colitis. Competitors are typically other systemic immune-modulating treatments used for the same diseases, especially biologics that target different inflammatory pathways.
For psoriasis and psoriatic arthritis, common competitor classes include:
- TNF inhibitors (for example, adalimumab, infliximab, certolizumab, golimumab, etanercept)
- IL-17 pathway inhibitors (for example, secukinumab, ixekizumab, brodalumab)
- IL-23 pathway inhibitors (for example, guselkumab, risankizumab, tildrakizumab)
For Crohn’s disease and ulcerative colitis, competitors include:
- TNF inhibitors
- Integrin blockers (for example, vedolizumab)
- IL-12/23 blockers (the same pathway family as ustekinumab, but with different products)
- IL-23 and other newer targeted agents (depending on indication and patient profile)
- JAK inhibitors (in some ulcerative colitis and related uses)
What are the main Stelara “biologic” competitors by mechanism?
Because Stelara blocks IL-12 and IL-23 signaling, direct “pathway-adjacent” biologic competition often comes from:
- IL-17 inhibitors (different downstream pathway, but overlapping psoriasis activity)
- IL-23 inhibitors (same upstream cytokine family focus, different binding target)
- TNF inhibitors (broad inflammatory pathway, long-established in multiple indications)
These differences matter because patients who don’t respond to Stelara—or who lose response—often switch within these competing classes based on guideline positioning, comorbidities, and prior biologic exposure.
Are IL-23 drugs Stelara’s closest competitors for plaque psoriasis?
In practice, IL-23 inhibitors are among the most common “swap” alternatives for patients with plaque psoriasis who are considering a change in therapy. They target a related cytokine axis and compete for similar prescriber decision-making across efficacy, dosing convenience, and insurance coverage.
Who competes with Stelara in Crohn’s disease and ulcerative colitis?
In inflammatory bowel disease, Stelara competes in a crowded space. Depending on the patient and prior treatments, clinicians may choose among:
- TNF inhibitors
- Integrin blockers (gut-selective)
- Other cytokine-targeting biologics, including IL-23/IL-12-23-related approaches and newer agents
- JAK inhibitors for ulcerative colitis in appropriate patients (when available/indicated)
Do biosimilars count as Stelara competitors?
Yes. If a ustekinumab biosimilar is available for the same indication, it directly competes with Stelara on price and access. Switching to a biosimilar can happen through payer policies and formulary decisions even when clinical response is stable.
If you want, tell me which Stelara indication you mean (psoriasis, psoriatic arthritis, Crohn’s, or ulcerative colitis), and I can narrow the list to the most relevant competitors for that specific use case.
DrugPatentWatch angle: where to check patent/exclusivity pressure
For competitive landscape shifts driven by patent expiry, biosimilar launches, and exclusivity timelines, DrugPatentWatch.com is a useful place to look up ustekinumab-related IP status and any relevant entries tied to competing products.
Source: DrugPatentWatch.com